...
首页> 外文期刊>Journal of molecular graphics & modelling >QSAR models for predicting cathepsin B inhibition by small molecules-Continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules
【24h】

QSAR models for predicting cathepsin B inhibition by small molecules-Continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules

机译:预测小分子组织蛋白酶B抑制的QSAR模型-连续和二元QSAR模型对小分子组织蛋白酶B抑制活性进行分类

获取原文
获取原文并翻译 | 示例
           

摘要

Cathepsin B is a potential target for the development of drugs to treat several important human diseases. A number of inhibitors targeting this protein have been developed in the past several years. Recently, a group of small molecules were identified to have inhibitory activity against cathepsin B through high throughput screening (HTS) tests. In this study, traditional continuous and binary QSAR models were built to classify the biological activities of previously identified compounds and to distinguish active compounds from inactive compounds for drug development based on the calculated molecular and physicochemical properties. Strong correlations were obtained for the continuous QSAR models with regression correlation coefficients (r~2) and cross-validated correlation coefficients (q~2) of 0.77 and 0.61 for all compounds, and 0.82 and 0.68 for the compound set excluding 3 outliers, respectively. The models were further validated through the leave-one-out (LOO) method and the training-test set method. The binary models demonstrated a strong level of predictability in distinguishing the active compounds from inactive compounds with accuracies of 0.89 and 0.94 for active and inactive compounds, respectively, in non-cross-validated models. Similar results were obtained for the cross-validated models. Collectively, these results demonstrate the models' ability to discriminate between active and inactive compounds, suggesting that the models may be used to pre-screen compounds to facilitate compound optimization and to design novel inhibitors for drug development.
机译:组织蛋白酶B是治疗多种重要人类疾病的药物开发的潜在目标。在过去的几年中已经开发出许多靶向该蛋白的抑制剂。最近,通过高通量筛选(HTS)测试,鉴定出一组小分子对组织蛋白酶B具有抑制活性。在这项研究中,建立了传统的连续和二元QSAR模型,以对先前鉴定出的化合物的生物学活性进行分类,并根据计算出的分子和理化特性将活性化合物与非活性化合物区分开来进行药物开发。对于连续QSAR模型,所有化合物的回归相关系数(r〜2)和交叉验证的相关系数(q〜2)分别为0.77和0.61,对于化合物集(不包括3个离群值)分别为0.82和0.68,具有很强的相关性。 。通过留一法(LOO)方法和训练测试集方法进一步验证了模型。在非交叉验证的模型中,二元模型在区分活性化合物和非活性化合物方面具有很强的可预测性,其活性和非活性化合物的准确度分别为0.89和0.94。对于交叉验证的模型,获得了相似的结果。这些结果共同证明了该模型区分活性和非活性化合物的能力,表明该模型可用于预筛选化合物以促进化合物优化并设计用于药物开发的新型抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号